Market Insights
The Genome editing market was valued at USD 3.7 Billion in 2020, and it is expected to reach a value of USD 19.4 Billion by 2027, at a CAGR of 22.90% over the forecast period (2020 - 2027).
Genome editing is a technique for making changes to the DNA of a cell or an organism. The process entails cutting DNA sequences to add or remove DNA from the genome. Changes to the genome are made to provide the cell the traits it needs. Various governments worldwide are expanding their assets and awards to foster genome-altering research. Attributable to genome altering's benefits, governments are also supporting public and private examination and scholastic foundations for expanding the exploration exercises for genome altering and hereditary designing. Hence, leading to positive market growth in the given forecast period.
Segmental Analysis
The rising predominance of disease and other hereditary issues, expanding inclination for customized medication, increase in R&D consumption and development of biotechnology and drug businesses, ascend in private and public area financing, quick progressions in sequencing, and Genome Editing advancements are factors impelling the genome editing market.
This report provides in-depth analysis of Global Genome editing market. We have analyzed 20+ data points that include product price trends, consumer purchase patterns, company annual sales performance, COVID-19 impact on distribution channels, parent industry performance, regional trends, and technological innovations, for tracking the Global market size and performance in the recent years.
Global Genome Editing Market Segmentation
The Global Genome editing market is segmented based on Technology, Delivery Method, Mode, End-use, Application and Region. Based on Technology it is categorized into: Meganucleases, (CRISPR)/Cas9, TALENs/MegaTALs, ZFN. Based on Delivery Method it is categorized into: Ex-vivo, In-vivo. Based on Mode it is categorized into: Contract, In-house. Based on End-use it is categorized into: Biotechnology and pharmaceutical companies, Academic and government research institutes, Contract research organizations. Based on region it is categorized into: North America, Europe, Asia-Pacific, South America, and MEA.
Regional Insights
Global Genome Editing Market: Impact of COVID 19
Covid-19 has become a global economic danger and has had a detrimental influence on a variety of sectors, including the genome editing market. The market's growth is projected to decrease as a result of lower discretionary income and shattered supply networks. The business is also harmed by a scarcity of qualified experts as a result of medical staff being reassigned to the Covid-19 frontlines. Low public awareness in developing countries and stringent government rules are also impeding industry expansion..
Key Trends in Global Genome Editing Market
-
The growing use of gene-editing technologies in therapeutic research has increased the number of sophisticated medicines entering clinical trials. In addition, using artificial intelligence to accelerate the deployment of innovative gene modification systems has a lot of promise for the technology developer. This is expected to substantially benefit market revenue.
Global Genome Editing Market: Regional Dynamics
North America dominated the genome editing market in 2020, accounting for 38.4% of total revenue. The dominance of the market in the region is due to the availability of strong research, as well as a commercial base for advanced therapeutic development, as well as a large number of clinical studies being undertaken for gene and stem cell therapies in the region. On the other hand, the market in the Asia Pacific is expected to expand at a rapid rate over the projected period. China unveiled its 10 most significant agricultural breakthroughs in November 2020, one of which was gene-editing technology, demonstrating strong market penetration.
Market Dynamics
Global Genome editing Market: Competitive Landscape
The market is characterized by the presence of a few well-established players. New product launches, partnerships and investing in research & development have been a key business strategy. Some of their recent developments are as follows:
-
In 2020, New England Biolabs and ERS Genomics partnered to develop and market CRISPR gene editing technologies and reagents.
-
In 2019, Brammer Bio was bought by Thermo Fisher Scientific to get access to Brammer Bio's expertise in producing vectors for gene and cell treatments.
-
In 2019, Horizon Discovery released predesigned synthetic single-guide RNA (sgRNA) to help researchers achieve targeted gene knockouts and perform DNA-gene-free editing.
Key players in Genome editing market are:
-
Merck KGaA
-
Cibus, Recombinetics, Inc.
-
Sangamo
-
Editas Medicine
-
Precision Biosciences
-
Ccispr Therapeutics
-
Intellia Therapeutics, Inc.
-
Caribou Biosciences, Inc.
-
Cellectis S.A.
-
AstraZeneca
-
Takara Bio USA
-
Horizon Discovery Group plc
-
Integrated DNA Technologies, Inc.
-
Egenesis Inc.
-
GenScript
-
New England Biolabs
-
OriGene Technologies, Inc.
-
Lonza
-
Thermo Fisher Scientific, Inc.
Scope of the Report
The study provides an analysis of the Global Genome editing Market in the emerging and established markets across the globe, including North America, Europe, Asia-Pacific, South America, and Middle East & Africa. For each segment, the market sizing and forecasts have been done on the basis of value.
